glp-1 agonist for prediabetes receptor agonists are transforming diabetes care by improving blood sugar control, supporting weight loss, and reducing cardiovascular risk when used appropriately. Evidence-based therapy selection, correct dosing, and patient counseling are Frontiers | GLP-1 Receptor Agonists:

Diabetes Ther 13(1):175187

Additionally, vascular endothelium becomes less effective at regulating blood flow and preventing clot formation, leading to endothelial dysfunction, increasing the risk of atherosclerosis, thrombosis, and other vascular diseases

To ensure patient safety and minimize potential gastrointestinal side effects like nausea or bloating, Semaglutide is always introduced at a low starting dose, typically 0.25 mg

These conclusions are based on a study involving 710 patients with Type 2 diabetes

Dispensing of glucagon-like peptide-1 receptor agonists to adolescents and young adults, 2020-2023

Thats according to a small clinical trial run by Novo Nordisk, so real-life results may vary